Pfizer (NYSE:PFE) Trading 0.4% Higher – Here’s What Happened

Pfizer Inc. (NYSE:PFE) shares rose 0.4% during trading on Friday . The company traded as high as $22.55 and last traded at $22.13. Approximately 53,854,504 shares traded hands during mid-day trading, an increase of 33% from the average daily volume of 40,458,828 shares. The stock had previously closed at $22.04.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on PFE shares. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. UBS Group lowered their price target on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating for the company in a research note on Tuesday, April 8th. Finally, Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $31.07.

Pfizer Price Performance

The stock has a market cap of $125.50 billion, a PE ratio of 15.69, a P/E/G ratio of 0.64 and a beta of 0.67. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The business has a fifty day simple moving average of $24.88 and a two-hundred day simple moving average of $26.17.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the prior year, the company earned $0.10 earnings per share. The firm’s quarterly revenue was up 24.7% compared to the same quarter last year. Research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insider Activity

In related news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.06% of the company’s stock.

Institutional Trading of Pfizer

Institutional investors have recently bought and sold shares of the company. Retirement Wealth Solutions LLC purchased a new position in Pfizer in the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC bought a new position in shares of Pfizer during the fourth quarter valued at $26,000. Clarity Asset Management Inc. purchased a new stake in shares of Pfizer during the fourth quarter valued at $27,000. Gould Capital LLC increased its holdings in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 493 shares in the last quarter. Finally, Kohmann Bosshard Financial Services LLC bought a new position in Pfizer during the 4th quarter valued at about $28,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.